RrcHSIL non-responders to imiquimod exhibited an even more immunosuppressive microenvironment than complete responders, characterized by increased infiltration of CD4 + FoxP3 + regulatory T cells and (CD14 + )CD68 + CD163 + M2-like macrophages and CD14 + HLADR- monocytic myeloid derived suppressor cells. The limited efficacy of imiquimod in rrcHSIL may be explained by a strong immunosuppressive microenvironment.

P1/2, N=140, Recruiting, United Immunity, co., Ltd. | Not yet recruiting --> Recruiting

DHU-OH-6 enables fluorescence imaging of exogenous and endogenous HOCl in cells and provides fluorescence-guided therapy in an imiquimod-induced psoriasis mouse model, where it alleviates psoriatic skin lesions and mitigates systemic toxicity relative to free CPT. This HOCl-activated hydroxyl drug-release platform offers a generalizable strategy for the design of site-selective, image-guided prodrugs for HOCl-overexpressing diseases.

P2, N=70, Active, not recruiting, Eikon Therapeutics | Recruiting --> Active, not recruiting

Mice were divided into five groups: control (cream base), imiquimod (IMQU; 62.5 mg/day for 7 days), a commonly used inducer of psoriasis-like dermatitis, standard (tacrolimus 20 mg/kg/day, 2 h after IMQU), IMQU + D...These findings suggest that D. tortuosa and D. triradiata NCs possess promising anti-psoriatic potential, through immunomodulatory and anti-inflammatory mechanisms, with D. tortuosa demonstrating superior efficacy. They may serve as effective natural alternatives to conventional psoriasis treatments.

P1/2, N=140, Not yet recruiting, United Immunity, co., Ltd.

P1/2, N=20, Not yet recruiting, Eikon Therapeutics Inc.

P1, N=45, Not yet recruiting, HighField Biopharmaceuticals Corporation

P2/3, N=750, Recruiting, Eikon Therapeutics | Not yet recruiting --> Recruiting

Here, we determined and compared the efficacy of sodium R-lipoate (NaRLA, 50 and 100 mg/kg body weight/day), given orally for 8 consecutive days, in a BALB/c mouse model of imiquimod-induced psoriatic skin inflammation, in comparison with the synthetic drug methotrexate (MTX). Furthermore, NaRLA resulted in a significant improvement (P < 0.001) on both Evans blue extravasation and mast cell degranulation, suggesting a reduction in inflammation and edema. Thus, our observations imply that NaRLA may serve as an effective agent for alleviating psoriatic skin inflammation via targeting IL-23/IL-17A axis and mast cell degranulation.

Toll-like receptor 7/8 agonists (TLR7/8a), such as resiquimod (R848), are highly potent in activating dendritic cells and thus hold promise for T cell-mediated tumor immunotherapies...Furthermore, the R848 functional concentration assay demonstrated that the micropump prolonged the treatment time of R848 drugs in tumors and reduced the requirement for higher doses, enhancing safety. Taken together, this study provides new insights into TLR7/8a immunotherapy for improved clinical performance, with potential benefits for patients with superficial tumors amenable to prolonged intratumoral infusion via micropump.

P3, N=1630, Not yet recruiting, VA Office of Research and Development | Trial completion date: May 2032 --> Aug 2032 | Trial primary completion date: May 2032 --> Aug 2032